Athenex, Inc. (ATNX)
Stock Price Chart
Key Info
| Market Cap | 986.03M |
| Revenue (ttm) | 122.86M |
| Net Income (ttm) | -107.95M |
| Shares Out | 81.63M |
| EPS (ttm) | -1.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Jul 16, 2020 |
| Last Price | $12.08 |
| Previous Close | $12.60 |
| Change ($) | -0.52 |
| Change (%) | -4.13% |
| Day's Open | 12.46 |
| Day's Range | 12.07 - 12.46 |
| Day's Volume | 87,498 |
| 52-Week Range | 5.63 - 20.27 |
More Stats
| Market Cap | 986.03M |
| Enterprise Value | 936.11M |
| Earnings Date (est) | Aug 18, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 81.63M |
| Float | 46.82M |
| EPS (basic) | -1.39 |
| EPS (diluted) | -1.39 |
| FCF / Share | -1.53 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 9.58M |
| Short Ratio | 14.27 |
| Short % of Float | 15.60% |
| Beta | 1.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 8.03 |
| PB Ratio | 5.73 |
| Revenue | 122.86M |
| Operating Income | -100.85M |
| Net Income | -107.95M |
| Free Cash Flow | -124.42M |
| Net Cash | 49.92M |
| Net Cash / Share | 0.61 |
| Gross Margin | -40.18% |
| Operating Margin | -82.09% |
| Profit Margin | -87.90% |
| FCF Margin | -101.28% |
| ROA | -24.29% |
| ROE | -85.91% |
| ROIC | -72.60% |
Analyst Summary
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Revenue | 101 | 89.10 | 38.04 | 20.55 | 13.94 |
| Revenue Growth | 13.61% | 134.21% | 85.12% | 47.38% | - |
| Gross Profit | 31.61 | 42.10 | 12.92 | 0.83 | 0.79 |
| Operating Income | -120 | -127 | -110 | -85.75 | -50.71 |
| Net Income | -124 | -117 | -131 | -87.72 | -50.60 |
| Shares Outstanding | 74.05 | 64.59 | 49.96 | 40.12 | 33.77 |
| Earnings Per Share | -1.67 | -1.82 | -2.63 | -2.19 | -1.50 |
| Operating Cash Flow | -97.46 | -109 | -81.51 | -47.87 | -33.76 |
| Capital Expenditures | -13.57 | -3.32 | -5.44 | -1.15 | -3.31 |
| Free Cash Flow | -111 | -113 | -86.95 | -49.02 | -37.07 |
| Cash & Equivalents | 161 | 107 | 51.04 | 41.75 | 54.03 |
| Total Debt | 63.88 | 46.76 | 1.98 | 33.01 | 3.65 |
| Net Cash / Debt | 96.94 | 60.66 | 49.06 | 8.74 | 50.38 |
| Assets | 310 | 231 | 140 | 106 | 120 |
| Liabilities | 134 | 102 | 49.69 | 71.22 | 20.90 |
| Book Value | 188 | 139 | 90.04 | 33.81 | 98.58 |
Company Profile
Company Details
| Full Name | Athenex, Inc. |
| Country | United States |
| Employees | 574 |
| CEO | Yiu Nam Lau |
Stock Information
| Ticker Symbol | ATNX |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Unique Identifier | NASDAQ: ATNX |
| IPO Date | June 14, 2017 |
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.